ATE474917T1 - Verfahren zur erhöhung der in-vivo-gewinnung therapeutischer polypeptide - Google Patents

Verfahren zur erhöhung der in-vivo-gewinnung therapeutischer polypeptide

Info

Publication number
ATE474917T1
ATE474917T1 AT07723889T AT07723889T ATE474917T1 AT E474917 T1 ATE474917 T1 AT E474917T1 AT 07723889 T AT07723889 T AT 07723889T AT 07723889 T AT07723889 T AT 07723889T AT E474917 T1 ATE474917 T1 AT E474917T1
Authority
AT
Austria
Prior art keywords
therapeutic polypeptides
increase
vivo recovery
polypeptides
recovery
Prior art date
Application number
AT07723889T
Other languages
English (en)
Inventor
Thomas Weimer
Hubert Metzner
Stefan Schulte
Wiegand Lang
Wilfried Wormsbaecher
Original Assignee
Csl Behring Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csl Behring Gmbh filed Critical Csl Behring Gmbh
Application granted granted Critical
Publication of ATE474917T1 publication Critical patent/ATE474917T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AT07723889T 2006-04-11 2007-04-02 Verfahren zur erhöhung der in-vivo-gewinnung therapeutischer polypeptide ATE474917T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06007552 2006-04-11
PCT/EP2007/002948 WO2007115724A2 (de) 2006-04-11 2007-04-02 Method of increasing the in vivo recovery of therapeutic polypeptides

Publications (1)

Publication Number Publication Date
ATE474917T1 true ATE474917T1 (de) 2010-08-15

Family

ID=36778259

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07723889T ATE474917T1 (de) 2006-04-11 2007-04-02 Verfahren zur erhöhung der in-vivo-gewinnung therapeutischer polypeptide

Country Status (12)

Country Link
US (3) US20100222554A1 (de)
EP (2) EP2007885B1 (de)
JP (1) JP2009533364A (de)
KR (1) KR101492422B1 (de)
AT (1) ATE474917T1 (de)
AU (1) AU2007236280B2 (de)
CA (1) CA2649199C (de)
DE (1) DE602007007923D1 (de)
DK (1) DK2007885T3 (de)
ES (1) ES2349024T3 (de)
PL (1) PL2007885T3 (de)
WO (1) WO2007115724A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1816201A1 (de) * 2006-02-06 2007-08-08 CSL Behring GmbH Modifizierter Koagulationsfaktor VIIa mit verbesserter 'half-life'-Stabiltät
US7939632B2 (en) * 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
US8754194B2 (en) * 2006-12-22 2014-06-17 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
AU2008311973B2 (en) * 2007-10-15 2013-10-03 Cangene Corporation Human Factor IX variants with an extended half life
AU2010284977A1 (en) * 2009-08-20 2012-03-29 Csl Behring Gmbh Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
SG10201913700SA (en) * 2010-07-09 2020-03-30 Bioverativ Therapeutics Inc Factor ix polypeptides and methods of use thereof
EP3461905B1 (de) * 2010-11-22 2020-08-05 Amicus Therapeutics, Inc. Neuartige signalsequenzen zur verbesserung der proteinexpression und der abscheidung rekombinanter enzyme und anderer proteine
HK1213521A1 (zh) * 2012-09-25 2016-07-08 Bioverativ Therapeutics Inc. Fix多肽的應用
EA037906B1 (ru) 2013-03-15 2021-06-04 Биовератив Терапьютикс Инк. Препараты полипептида фактора ix
WO2020077114A2 (en) 2018-10-10 2020-04-16 Amicus Therapeutics, Inc. Disulfide bond stabilized polypeptide compositions and methods of use
WO2020084161A1 (en) * 2018-10-26 2020-04-30 Vrije Universiteit Brussel New tools for improving gene therapy and use thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4970300A (en) * 1985-02-01 1990-11-13 New York University Modified factor VIII
GR860984B (en) * 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US5364771A (en) * 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
EP0793504B1 (de) * 1994-12-12 2005-06-08 Beth Israel Deaconess Medical Center, Inc. Chimäre zytokine und ihre verwendung
DE19538715A1 (de) 1995-10-18 1997-04-30 Behringwerke Ag Verfahren zur Reinigung von Faktor VII und aktiviertem Faktor VII
JP3735921B2 (ja) * 1996-02-07 2006-01-18 三菱ウェルファーマ株式会社 ＧＰＩｂ・脂質複合体およびその用途
US6458563B1 (en) * 1996-06-26 2002-10-01 Emory University Modified factor VIII
CA2330527A1 (en) * 1998-06-15 1999-12-23 Genzyme Transgenics Corporation Erythropoietin analog-human serum albumin fusion
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
PL204285B1 (pl) * 2000-02-11 2009-12-31 Bayer Healthcare Llc Koniugat polipeptydowy, polipeptyd, sekwencja nukleotydowa, wektor ekspresyjny, komórka gospodarz, sposób wytwarzania koniugatu polipeptydowego, środek farmaceutyczny i zastosowanie koniugatu polipeptydowego
JP2003530838A (ja) 2000-04-12 2003-10-21 ヒューマン ゲノム サイエンシズ インコーポレイテッド アルブミン融合タンパク質
AU9165201A (en) * 2000-10-02 2002-04-15 Novo Nordisk As Factor vii glycoforms
JP4071105B2 (ja) * 2000-10-18 2008-04-02 マキシゲン・エイピーエス プロテインｃまたは活性化プロテインｃ様分子
EP1444986A1 (de) * 2003-02-07 2004-08-11 Aventis Behring GmbH Pharmazeutische Zusammensetzung zur verbesserten Behandlung von Krankheiten mit verminderter Blutgerinnung
TWI353991B (en) * 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
EP1745141B2 (de) * 2004-05-04 2019-09-25 Novo Nordisk Health Care AG O-verknüpfte glykoformen von faktor vii und verfahren zu deren herstellung
EP1816201A1 (de) * 2006-02-06 2007-08-08 CSL Behring GmbH Modifizierter Koagulationsfaktor VIIa mit verbesserter 'half-life'-Stabiltät
EP1867660A1 (de) * 2006-06-14 2007-12-19 CSL Behring GmbH Fusionsprotein welches proteolytisch geschnitten werden kann und einen Faktor der Blutgerinnungskaskade enthält
US7939632B2 (en) * 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
US8754194B2 (en) * 2006-12-22 2014-06-17 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life

Also Published As

Publication number Publication date
CA2649199C (en) 2015-01-20
US20100222554A1 (en) 2010-09-02
KR101492422B1 (ko) 2015-02-12
ES2349024T3 (es) 2010-12-21
WO2007115724A2 (de) 2007-10-18
DK2007885T3 (da) 2010-11-08
CA2649199A1 (en) 2007-10-18
EP2007885A2 (de) 2008-12-31
PL2007885T3 (pl) 2010-12-31
DE602007007923D1 (de) 2010-09-02
EP2263696A1 (de) 2010-12-22
JP2009533364A (ja) 2009-09-17
KR20090008329A (ko) 2009-01-21
AU2007236280B2 (en) 2013-07-25
US20140248686A1 (en) 2014-09-04
WO2007115724A3 (de) 2008-03-20
AU2007236280A1 (en) 2007-10-18
EP2007885B1 (de) 2010-07-21
US20130337532A1 (en) 2013-12-19

Similar Documents

Publication Publication Date Title
ATE474917T1 (de) Verfahren zur erhöhung der in-vivo-gewinnung therapeutischer polypeptide
CL2009001258A1 (es) Polipeptido multivalente que comprende dos dominios de fibronectina tipo iii, ligados por un polipeptido de engarce basado en glicina-serina o glicina-prolina.
JOP20190083A1 (ar) بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
CY1122195T1 (el) Πολυπεπτιδια συντηξης σερπινης και μεθοδοι χρησης αυτων
GT200700059A (es) Proteinas de fusion de exendina
SG171670A1 (en) Rage fusion proteins, formulations, and methods of use thereof
MX2008002101A (es) Fusiones de la proteina-1 quimiotactica de monocito.
WO2011101681A3 (en) Disulphide bond-stabilized functional soluble mhc class ii heterodimers
NZ703581A (en) Anti-cd70 antibody drug conjugates
UY31123A1 (es) Proteinas de fusion natriureticas
WO2013075066A3 (en) Variant serum albumin with improved half -life and other properties
WO2007130453A3 (en) Non-natural amino acid substituted polypeptides
SG162687A1 (en) Caustic stable chromatography ligands
MX359680B (es) Vacunas peptídicas para cánceres que expresan antígenos hig2 asociados con tumores.
SA112330988B1 (ar) أجسام مضادة تخص trop-2 واستخداماتها
ECSP12011577A (es) Produccion recombinante de péptidos
IL220164B (en) A method for purifying a purified antibody, antibody fragment, or fc-fused protein using an affinity chromatography matrix
WO2008114149A3 (en) Respiratory syncytial virus (rsv) chimeric polypeptide comprising the g protein central region domain located in between the f2 and f1 fusion protein domains
WO2010023670A3 (en) Methods for covalently attaching a polymer to a methionine residue in proteins and peptides
ATE426174T1 (de) Verfahren zum nachweis der amyloid-beta oligomere in kírperflussigkeiten
ATE527345T1 (de) Chimäres fusionsprotein mit überlegenen chaperon- und faltungsaktivitäten
NZ724196A (en) Uti fusion proteins
EP2091550A4 (de) Verfahren zur förderung von herzregeneration mittels an heparinbindende sequenzen fusionierte wachstumsfaktoren
WO2009025300A1 (ja) イミュノグロブリン結合能を有するペプチド
WO2009138494A3 (en) Amino acid sequences directed against toll-like receptors and their use for the treatment of diseases related to toll-like receptors

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2007885

Country of ref document: EP